Cargando…

Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease

Fabry disease is a rare lysosomal storage disorder caused by mutations in the GLA gene, which, without treatment, can cause significant renal dysfunction. We evaluated the effects of enzyme replacement therapy with agalsidase alfa on renal decline in patients with Fabry disease using data from the F...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cybulla, Markus, Nicholls, Kathleen, Feriozzi, Sandro, Linhart, Aleš, Torras, Joan, Vujkovac, Bojan, Botha, Jaco, Anagnostopoulou, Christina, West, Michael L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410255/ https://www.ncbi.nlm.nih.gov/pubmed/36013057 http://dx.doi.org/10.3390/jcm11164810

Ejemplares similares

Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis
por: Hughes, Derralynn, et al.
Publicado: (2021)

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
por: Goláň, Lubor, et al.
Publicado: (2015)

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
por: Linhart, Aleš, et al.
Publicado: (2023)

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
por: Arends, Maarten, et al.
Publicado: (2018)

Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis
por: Ramaswami, Uma, et al.
Publicado: (2019)

Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
por: Pisani, Antonio, et al.
Publicado: (2015)

Agalsidase alfa (Replagal(™)) in the treatment of Anderson-Fabry disease
por: Pastores, Gregory M
Publicado: (2007)

Update on role of agalsidase alfa in management of Fabry disease
por: Ramaswami, Uma
Publicado: (2011)

Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
por: Tsuboi, Kazuya, et al.
Publicado: (2012)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
por: Beck, Michael, et al.
Publicado: (2015)

Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis
por: Wanner, Christoph, et al.
Publicado: (2020)

CORRIGENDUM: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
Publicado: (2012)

Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy
por: Warnock, David G, et al.
Publicado: (2015)

The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process
por: Khan, Aneal, et al.
Publicado: (2021)

Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
por: Kampmann, Christoph, et al.
Publicado: (2015)

Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients
por: Tsuboi, Kazuya, et al.
Publicado: (2017)

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation
por: Warnock, David G., et al.
Publicado: (2012)

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
por: Ortiz, Alberto, et al.
Publicado: (2016)

Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
por: Kampmann, Christoph, et al.
Publicado: (2016)

Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study
por: Schiffmann, Raphael, et al.
Publicado: (2014)

Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α
por: Tsuboi, Kazuya, et al.
Publicado: (2014)

Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg
por: Vedder, Anouk C., et al.
Publicado: (2007)

An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
por: Goker-Alpan, Ozlem, et al.
Publicado: (2016)

Fabry nephropathy: a review – how can we optimize the management of Fabry nephropathy?
por: Waldek, Stephen, et al.
Publicado: (2014)

Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype
por: Hopkin, Robert J., et al.
Publicado: (2020)

Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events
por: Beck, Michael, et al.
Publicado: (2017)

Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation
por: van Kuilenburg, André B. P., et al.
Publicado: (2023)

Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative
por: Hughes, Derralynn A, et al.
Publicado: (2020)

Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age
por: Parini, Rossella, et al.
Publicado: (2020)

Biomarkers of Fabry Nephropathy: Review and Future Perspective
por: Levstek, Tina, et al.
Publicado: (2020)

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients
por: Smid, Bouwien E, et al.
Publicado: (2011)

Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
por: Germain, Dominique P, et al.
Publicado: (2015)

Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry
por: Beck, Michael, et al.
Publicado: (2022)

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered
por: Ortiz, Alberto, et al.
Publicado: (2015)

Podocyturia in Fabry disease: a 10-year follow-up
por: Vujkovac, Bojan, et al.
Publicado: (2021)

Letter concerning “Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha”, by Tanaka et al.
por: Linthorst, Gabor E., et al.
Publicado: (2010)

Urinary-derived extracellular vesicles reveal a distinct microRNA signature associated with the development and progression of Fabry nephropathy
por: Levstek, Tina, et al.
Publicado: (2023)

Paricalcitol as an Antiproteinuric Agent Can Result in the Deterioration of Renal and Heart Function in a Patient with Fabry Disease
por: Keber, Tajda, et al.
Publicado: (2017)

Reduction of agalsidase beta infusion time in patients with fabry disease: A case series report and suggested protocol
por: Sánchez-Purificación, Aquilino, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d05cic1krf11qfd2jnisj7ot0k